---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-113898"
form_type: "8-K"
ticker: "AVBP"
cik: "0001868279"
company_name: "ArriVent BioPharma, Inc."
filed_at: "2026-10-06T12:07:09+00:00"
generated_at: "2026-10-12T16:33:17.756173+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ArriVent's Phase 3 FURVENT trial misses primary PFS endpoint; firmonertinib 240mg PFS 11.0 vs 9.5 months (p=0.0654)

## Summary
- FURVENT Phase 3 trial of firmonertinib in first-line EGFR exon 20 insertion NSCLC missed primary endpoint of PFS by BICR: 240mg 11.0 months vs control 9.5 months, p=0.0654, HR 0.75.
- 160mg arm median PFS 8.4 months, HR 0.91; investigator-assessed PFS 11.1 vs 8.3 vs 7.1 months, HR 0.61 (0.46, 0.81) for 240mg vs control.
- Confirmed ORR by BICR: 60% for firmonertinib 240mg, 35% for 160mg, 33% for control; investigator-assessed ORR 61%, 41%, 28%.
- Safety consistent with prior studies, no new signals; Grade >=3 TEAEs 52% (240mg), 53% (160mg), 55% (control); Grade >=3 TRAEs 26%, 22%, 40%.
- CEO Bing Yao called the results 'disappointing'; ArriVent says it is evaluating the full FURVENT dataset to determine the most appropriate development path for firmonertinib.

## SEC filing metadata
- accession: 0001104659-26-113898
- form_type: 8-K
- ticker: AVBP
- cik: 0001868279
- company_name: ArriVent BioPharma, Inc.
- filed_at: 2026-10-06T12:07:09+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1868279/000110465926113898/0001104659-26-113898-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1868279/000110465926113898/tm2627092d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-113898
- JSON: https://secwatch.observer/filing/0001104659-26-113898.json
- Plain text: https://secwatch.observer/filing/0001104659-26-113898.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.